Inhibition of C1GALT1 using a genetic or pharmacological inhibitor, such as ITZ, reduces SMO O-glycosylation, Hh signaling, and EWSR1::FLI1 expression, resulting in decreased ES cell viability and tumor growth in mice. The gene discussed is SMO; the disease is neoplasm.